{"id":"darbepoetin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Hypertension","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Convulsions","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Hypertensive disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Hypertension","drugRate":"","severity":"serious"},{"effect":"Convulsions","drugRate":"","severity":"serious"},{"effect":"Cerebrovascular disorders","drugRate":"","severity":"serious"},{"effect":"Thromboembolic adverse reactions","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Darbe","EPO"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"0fd36cb9-c4f6-4167-93c9-8530865db3f9","title":"ARANESP (DARBEPOETIN ALFA) INJECTION, SOLUTION ARANESP (DARBEPOETIN ALFA) SOLUTION [AMGEN, INC]"},"ecosystem":[],"mechanism":{"target":"Erythropoietin receptor"},"_scrapedAt":"2026-03-28T01:08:43.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Anemia due to and following chemotherapy","diseaseId":"anemia-due-to-and-following-chemotherapy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Anemia of renal disease","diseaseId":"anemia-of-renal-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07096297","phase":"PHASE2","title":"Luspatercept + Darbepoetin in MDS","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-16","conditions":"MDS (Myelodysplastic Syndrome)","enrollment":60},{"nctId":"NCT06520826","phase":"PHASE3","title":"Vafseo Outcomes In-Center Experience","status":"ACTIVE_NOT_RECRUITING","sponsor":"USRC Kidney Research","startDate":"2024-11-20","conditions":"Anemia of Chronic Kidney Disease","enrollment":2200},{"nctId":"NCT06184867","phase":"NA","title":"Choices About Genetic Testing And Learning Your Risk With Smart Technology","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-09-26","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":50},{"nctId":"NCT05340465","phase":"PHASE2","title":"Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-11-27","conditions":"Prematurity, Iron-deficiency, Iron Deficiency Anemia","enrollment":120},{"nctId":"NCT03329196","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-10-30","conditions":"Anemia; Non-dialysis Dependent Chronic Kidney Disease","enrollment":304},{"nctId":"NCT03439137","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-02-14","conditions":"Anemia; Hemodialysis Dependent Chronic Kidney Disease","enrollment":323},{"nctId":"NCT07300111","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-12-31","conditions":"Anaemia","enrollment":100},{"nctId":"NCT07169643","phase":"PHASE3","title":"Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-11-25","conditions":"Liver Transplant; Complications","enrollment":140},{"nctId":"NCT03810911","phase":"PHASE2","title":"Mechanisms of EPO-induced Hypertension","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2021-01-04","conditions":"Chronic Kidney Disease, Blood Pressure, Anemia","enrollment":27},{"nctId":"NCT07130487","phase":"NA","title":"Project CARE: CAncer Risk Evaluation","status":"RECRUITING","sponsor":"Anita Y. Kinney, PhD, RN","startDate":"2025-11-19","conditions":"Primary Care","enrollment":210},{"nctId":"NCT03169881","phase":"PHASE3","title":"Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"2017-09-20","conditions":"Neurocognitive, Neuroprotective, Neonatal","enrollment":650},{"nctId":"NCT04798339","phase":"PHASE1, PHASE2","title":"Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-03-30","conditions":"Myelodysplastic Syndromes","enrollment":13},{"nctId":"NCT07025460","phase":"PHASE4","title":"Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gangnam Severance Hospital","startDate":"2019-12-19","conditions":"Chronic Kidney Disease","enrollment":40},{"nctId":"NCT07131280","phase":"NA","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-09","conditions":"Decompensated Cirrhosis","enrollment":110},{"nctId":"NCT07119372","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-01","conditions":"Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis","enrollment":228},{"nctId":"NCT07002827","phase":"NA","title":"Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-05-30","conditions":"Decompensated Liver Cirrhosis","enrollment":60},{"nctId":"NCT04313153","phase":"PHASE3","title":"Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2020-05-27","conditions":"Anemia","enrollment":319},{"nctId":"NCT06903559","phase":"PHASE1, PHASE2","title":"Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":"Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease","enrollment":46},{"nctId":"NCT06917950","phase":"PHASE1, PHASE2","title":"Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":"Kidney Failure,Chronic, Anemia in End Stage Renal Disease, Depression Anxiety Disorder","enrollment":46},{"nctId":"NCT05636891","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2021-09-19","conditions":"Chronic Kidney Disease","enrollment":43},{"nctId":"NCT05585645","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2019-08-08","conditions":"Anemia, Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":214},{"nctId":"NCT01196715","phase":"PHASE3","title":"Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-11-01","conditions":"Myelodysplastic Syndrome","enrollment":360},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","enrollment":30},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":616},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":"Chronic Kidney Disease","enrollment":334},{"nctId":"NCT02952092","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-30","conditions":"Hemodialysis Chronic Kidney Disease Patients With Anemia","enrollment":303},{"nctId":"NCT01888445","phase":"PHASE2","title":"A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03-28","conditions":"Renal Anemia Associated With Chronic Renal Failure (CRF)","enrollment":130},{"nctId":"NCT01471015","phase":"PHASE1, PHASE2","title":"Darbe Administration in Newborns Undergoing Cooling for Encephalopathy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2012-09","conditions":"Hypoxic Ischemic Encephalopathy","enrollment":30},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT02876835","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-27","conditions":"Anaemia","enrollment":3872},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT04432662","phase":"PHASE2","title":"Darbepoetin in Neonatal Encephalopathy Trial","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2021-05-28","conditions":"Neonatal Encephalopathy","enrollment":150},{"nctId":"NCT05936021","phase":"NA","title":"Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model","status":"UNKNOWN","sponsor":"Intermountain Health Care, Inc.","startDate":"2023-07-01","conditions":"Dialysis","enrollment":80},{"nctId":"NCT02987465","phase":"","title":"Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-02-20","conditions":"Cardiovascular Diseases, Chronic Kidney Disease","enrollment":29},{"nctId":"NCT04330729","phase":"NA","title":"The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp","status":"RECRUITING","sponsor":"Zealand University Hospital","startDate":"2020-04-15","conditions":"Erythropoietin Adverse Reaction","enrollment":60},{"nctId":"NCT03071861","phase":"PHASE2","title":"Mild Encephalopathy in the Newborn Treated With Darbepoetin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2017-12-01","conditions":"Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild","enrollment":28},{"nctId":"NCT03171818","phase":"PHASE2","title":"Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2017-07-01","conditions":"PAIS, Neonatal Stroke, Perinatal Stroke","enrollment":80},{"nctId":"NCT05864261","phase":"PHASE4","title":"Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers","status":"COMPLETED","sponsor":"Yi Fang","startDate":"2023-05-15","conditions":"Renal Anemia","enrollment":74},{"nctId":"NCT01207778","phase":"","title":"Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2010-03","conditions":"Prematurity","enrollment":77},{"nctId":"NCT00146562","phase":"PHASE2","title":"Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Harold J. Burstein, MD, PhD","startDate":"2003-07","conditions":"Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer","enrollment":135},{"nctId":"NCT05768997","phase":"PHASE3","title":"High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2023-03-01","conditions":"Anemia","enrollment":312},{"nctId":"NCT05699109","phase":"","title":"Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-01-01","conditions":"Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia","enrollment":127},{"nctId":"NCT00858364","phase":"PHASE3","title":"Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy","status":"TERMINATED","sponsor":"Amgen","startDate":"2009-07-17","conditions":"Non-Small Cell Lung Cancer, Anemia, Cancer","enrollment":2549},{"nctId":"NCT00436748","phase":"PHASE3","title":"Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2008-09-16","conditions":"Anemia, Chronic Kidney Disease, Kidney Disease","enrollment":116},{"nctId":"NCT00093015","phase":"PHASE3","title":"Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Kidney Disease, Diabetes Mellitus, Anemia","enrollment":4038},{"nctId":"NCT00358215","phase":"PHASE3","title":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-01","conditions":"Heart Failure, Anemia, Cardiovascular Disease","enrollment":2278},{"nctId":"NCT01652872","phase":"PHASE3","title":"Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-07-30","conditions":"Anemia in Chronic Kidney Disease Patients Not on Dialysis","enrollment":756},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT02865850","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-07","conditions":"Anemia, Dialysis-Dependent Chronic Kidney Disease","enrollment":369},{"nctId":"NCT02892149","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-08","conditions":"Anemia, Dialysis-Dependent Chronic Kidney Disease","enrollment":3554},{"nctId":"NCT02680574","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-02","conditions":"Anemia, Non-Dialysis-Dependent Chronic Kidney Disease","enrollment":1725},{"nctId":"NCT02648347","phase":"PHASE3","title":"Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2015-12","conditions":"Anemia, Non-Dialysis-Dependent Chronic Kidney Disease","enrollment":1751},{"nctId":"NCT02879305","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-28","conditions":"Anaemia, Aspergillosis, Allergic Bronchopulmonary","enrollment":2964},{"nctId":"NCT04012957","phase":"PHASE3","title":"Desidustat in the Treatment of Anemia in CKD","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2019-07-20","conditions":"Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4","enrollment":588},{"nctId":"NCT02273726","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-01-15","conditions":"CKD Anemia in Stable Dialysis Patients","enrollment":741},{"nctId":"NCT03029208","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-11","conditions":"Anaemia","enrollment":312},{"nctId":"NCT00153868","phase":"PHASE4","title":"A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2003-10","conditions":"Anemia, Cancer","enrollment":43},{"nctId":"NCT00642967","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Anemia","enrollment":127},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT01506947","phase":"PHASE4","title":"A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05-10","conditions":"Moderate to Severe Secondary Hyperparathyroidism, Stage 5 Chronic Kidney Diseases","enrollment":65},{"nctId":"NCT04959578","phase":"PHASE4","title":"Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Rufaida Mazahir","startDate":"2018-02-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":50},{"nctId":"NCT02241200","phase":"PHASE1","title":"A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-08-18","conditions":"Symptomatic Anemia","enrollment":64},{"nctId":"NCT04027517","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-01-15","conditions":"Anemia of Chronic Kidney Disease","enrollment":172},{"nctId":"NCT03519243","phase":"PHASE2","title":"Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-10-24","conditions":"Anemia","enrollment":75},{"nctId":"NCT03543657","phase":"PHASE3","title":"Maintenance Treatment of Renal Anemia in Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-23","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":229},{"nctId":"NCT03350321","phase":"PHASE3","title":"A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-12","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":162},{"nctId":"NCT03350347","phase":"PHASE3","title":"A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-13","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":164},{"nctId":"NCT02969655","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-21","conditions":"Anaemia","enrollment":271},{"nctId":"NCT00058422","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-02-10","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT03992066","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2019-05-28","conditions":"Anemia Associated With Chronic Kidney Disease","enrollment":46},{"nctId":"NCT00070382","phase":"PHASE3","title":"Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-08","conditions":"Anemia, Leukemia, Lymphoma","enrollment":14},{"nctId":"NCT02136563","phase":"","title":"Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2014-04","conditions":"Renal Anemia, Chronic Kidney Disease","enrollment":2000},{"nctId":"NCT00883415","phase":"","title":"Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2008-05","conditions":"Cardiomyopathy, Chronic Kidney Disease, Anemia","enrollment":20},{"nctId":"NCT02506868","phase":"PHASE3","title":"Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-08-08","conditions":"Chronic Kidney Disease, End Stage Renal Failure on Dialysis, Anemia","enrollment":196},{"nctId":"NCT03693950","phase":"PHASE1","title":"The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-03-28","conditions":"Healthy","enrollment":57},{"nctId":"NCT02890602","phase":"PHASE2","title":"Erythropoietin for Management of Anemia Caused by Chemotherapy","status":"COMPLETED","sponsor":"Kosin University Gospel Hospital","startDate":"2012-09-01","conditions":"Diffuse Large B-cell Lymphoma","enrollment":53},{"nctId":"NCT03104426","phase":"PHASE2, PHASE3","title":"EPO-4-Rhesus Study","status":"UNKNOWN","sponsor":"Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research","startDate":"2017-10-31","conditions":"Erythroblastosis, Fetal, Erythroblastosis Fetalis, Rh Disease, Erythroblastosis Fetalis Due to RH Antibodies","enrollment":42},{"nctId":"NCT02021409","phase":"PHASE2","title":"Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01-28","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":126},{"nctId":"NCT02817555","phase":"PHASE4","title":"Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Andrea L Woodland","startDate":"2010-09","conditions":"Anemia, Chronic Kidney Disease","enrollment":50},{"nctId":"NCT00773513","phase":"PHASE4","title":"A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-12","conditions":"Chronic Renal Anemia","enrollment":2825},{"nctId":"NCT02731469","phase":"PHASE1","title":"Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-06-15","conditions":"Reticulocyte Count","enrollment":45},{"nctId":"NCT02912494","phase":"PHASE3","title":"A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2016-09","conditions":"Anemia","enrollment":""},{"nctId":"NCT03861637","phase":"NA","title":"Impact of Full Correction of PTA in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hamid Al-Essa Organ Transplant Center","startDate":"2015-01-20","conditions":"Anemia","enrollment":280},{"nctId":"NCT00334737","phase":"PHASE2","title":"Darbepoetin Administration to Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-06","conditions":"Infant, Newborn","enrollment":102},{"nctId":"NCT03776032","phase":"PHASE3","title":"A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"1999-09-14","conditions":"Anemia","enrollment":320},{"nctId":"NCT02175277","phase":"PHASE3","title":"Darbepoetin Alfa MDS Companion Protocol","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-06-12","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":9},{"nctId":"NCT00283621","phase":"NA","title":"Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-06-02","conditions":"Sarcoma","enrollment":51},{"nctId":"NCT03242967","phase":"PHASE3","title":"Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)","status":"WITHDRAWN","sponsor":"Akebia Therapeutics","startDate":"2017-08","conditions":"Anemia, Dialysis-Dependent Chronic Kidney Disease","enrollment":""},{"nctId":"NCT01977573","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-31","conditions":"Anaemia","enrollment":252},{"nctId":"NCT00398047","phase":"PHASE2","title":"Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2006-09","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":3},{"nctId":"NCT00642304","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03-27","conditions":"Anemia","enrollment":20},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT03542916","phase":"PHASE1","title":"Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2014-10","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT00281892","phase":"PHASE3","title":"Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2004-09","conditions":"Chronic Lymphocytic Leukemia, Anemia","enrollment":97},{"nctId":"NCT01581073","phase":"PHASE3","title":"PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2012-02-16","conditions":"Chronic Kidney Disease, Diabetes","enrollment":476},{"nctId":"NCT03431623","phase":"PHASE3","title":"CKD-11101 Phase 3 SC Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-05","conditions":"Anemia of Chronic Kidney Disease","enrollment":248},{"nctId":"NCT03428594","phase":"PHASE3","title":"CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-06","conditions":"Anemia of Chronic Kidney Disease","enrollment":403}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1445,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Darbepoetin","genericName":"Darbepoetin","companyName":"NICHD Neonatal Research Network","companyId":"nichd-neonatal-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}